TuHURA Biosciences, Inc. (HURA) 10-Year Financial Performance & Capital Metrics

HURA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutTuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.Show more

Revenue $0
EBITDA -$18M +40.7%
Net Income -$22M +26.0%
EPS (Diluted) -1.21 +89.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -332.67% +39.0%
ROIC -
Debt/Equity 0.01
Interest Coverage -4.26 +99.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM91.74%

ROCE

10Y Avg-283.61%

5Y Avg-278.35%

3Y Avg-285.19%

Latest-229.18%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	10.29K	16.68K	24.53K	16.35K	10K	32K	0	0	0	116.71K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10.29K	-16.68K	-24.53K	-16.35K	-10K	-32K	0	0	0	-116.71K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.62%	-0.47%	0.33%	0.39%	-2.2%	1%	-	-	-
Operating Expenses+	6.2M	8.3M	11.15M	8.38M	8.13M	21.54M	7.25M	9.93M	29.76M	17.53M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.84M	3.3M	4.02M	4.72M	4.5M	9.72M	2.38M	2.01M	4.14M	4.2M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.36M	5M	7.13M	3.66M	3.63M	11.81M	4.88M	7.93M	9.4M	13.34M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	16.22M	0
Operating Income+	-6.21M	-8.32M	-11.17M	-8.4M	-8.14M	-21.57M	-7.25M	-9.93M	-29.76M	-17.65M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.32%	-0.34%	-0.34%	0.25%	0.03%	-1.65%	0.66%	-0.37%	-2%	0.41%
EBITDA+	-6.2M	-8.3M	-11.15M	-8.38M	-8.13M	-21.54M	-6.87M	-9.56M	-29.59M	-17.53M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.43%	-0.34%	-0.34%	0.25%	0.03%	-1.65%	0.68%	-0.39%	-2.09%	0.41%
D&A (Non-Cash Add-back)	10.29K	16.68K	24.53K	16.35K	10K	32K	380.69K	373.09K	177.38K	116.71K
EBIT	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.18M	-6.39M	-9.93M	-29.3M	-17.54M
Net Interest Income+	108	457	33.24K	60.7K	75K	-120K	-629.29K	57.35K	70.98K	-3.78M
Interest Income	108	457	33.24K	60.7K	75K	0	0	57.35K	89.67K	361.63K
Interest Expense	0	0	0	0	0	120K	629.29K	0	18.69K	4.14M
Other Income/Expense	-2.65M	239.06K	36.35K	350.27K	-982K	-16.73M	238.47K	566.34K	447.89K	-4.03M
Pretax Income+	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.04%	0.09%	-0.38%	0.28%	-0.13%	-3.2%	0.82%	-0.34%	-2.13%	0.26%
Net Income (Continuing)	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14525.00	-12950.00	-9491.48	-5525.00	-1532.00	-2805.85	-903.04	-324.48	-11.29	-1.21
EPS Growth %	-0.89%	0.11%	0.27%	0.42%	0.72%	-0.83%	0.68%	0.64%	0.97%	0.89%
EPS (Basic)	-14525.00	-12950.00	-9491.48	-5525.00	-1532.00	-2805.85	-903.04	-324.48	-11.29	-1.21
Diluted Shares Outstanding	626	688	1.19K	1.47K	5.97K	14.79K	27.83K	46.28K	752.91K	18.66M
Basic Shares Outstanding	626	688	1.19K	1.47K	5.97K	14.79K	27.83K	46.28K	752.91K	18.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.32M	7.87M	7.05M	4.03M	2.76M	11.79M	5.68M	14.74M	4.16M	19.61M
Cash & Short-Term Investments	6.16M	6.59M	5.97M	3.72M	2.39M	10.54M	5.55M	14.25M	3.67M	12.66M
Cash Only	6.16M	6.59M	5.97M	3.72M	2.39M	10.54M	5.55M	14.25M	3.67M	12.66M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	18.39K	76.59K	39.52K	26.19K	0	0	0	101.42K	334.44K	222.7K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	214.7K
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	671.45
Other Current Assets	0	1.21M	1.03M	280.25K	365K	1.26M	135.13K	390.35K	159.33K	316.35K
Total Non-Current Assets+	36.02K	40.29K	28.41K	12.06K	181K	1.75M	721.04K	452.32K	202.99K	356.3K
Property, Plant & Equipment	0	0	0	0	2K	150K	617.14K	418.55K	202.99K	322.53K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	36.02K	40.29K	28.41K	12.06K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	179K	1.6M	103.9K	33.77K	0	33.77K
Total Assets+	6.36M	7.91M	7.07M	4.04M	2.94M	13.54M	6.4M	15.2M	4.36M	19.97M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.47%	0.24%	-0.11%	-0.43%	-0.27%	3.61%	-0.53%	1.37%	-0.71%	3.58%
Total Current Liabilities+	627.45K	1.3M	1.64M	2.07M	2.67M	2.78M	7.15M	2.87M	3.6M	5.33M
Accounts Payable	627.45K	1.27M	1.48M	1.74M	2.01M	2.22M	413.79K	1.92M	1.87M	3.15M
Days Payables Outstanding	22.26K	27.81K	22K	38.95K	73.4K	25.31K	-	-	-	9.86K
Short-Term Debt	0	0	0	0	0	0	644.07K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	33.09K	160.43K	325.21K	664K	561K	456K	675K	137K	1.16M
Current Ratio	10.07x	6.03x	4.30x	1.94x	1.03x	4.24x	0.79x	5.13x	1.16x	3.68x
Quick Ratio	10.07x	6.03x	4.30x	1.94x	1.03x	4.24x	0.79x	5.13x	1.16x	3.64x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	869.58K	28.14K	1.12K	0	0	182K	0	20.74K	2.32M	42.7K
Long-Term Debt	0	0	0	0	0	0	0	0	2.32M	0
Capital Lease Obligations	0	0	0	0	0	0	0	20.74K	0	42.7K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	869.58K	28.14K	1.12K	0	0	182K	0	0	0	0
Total Liabilities	1.5M	1.33M	1.64M	2.07M	2.67M	2.96M	7.15M	2.89M	5.92M	5.37M
Total Debt+	0	0	0	0	0	0	644.07K	138.22K	2.34M	202.54K
Net Debt	-6.16M	-6.59M	-5.97M	-3.72M	-2.39M	-10.54M	-4.9M	-14.11M	-1.32M	-12.45M
Debt / Equity	-	-	-	-	-	-	-	0.01x	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-179.77x	-11.53x	-	-1592.72x	-4.26x
Total Equity+	4.86M	6.58M	5.44M	1.97M	263K	10.58M	-747.82K	12.3M	-1.56M	14.59M
Equity Growth %	6.91%	0.35%	-0.17%	-0.64%	-0.87%	39.23%	-1.07%	17.45%	-1.13%	10.36%
Book Value per Share	7766.25	9556.19	4559.75	1337.55	44.07	715.37	-26.87	265.83	-2.07	0.78
Total Shareholders' Equity	4.86M	6.58M	5.44M	1.97M	263K	10.58M	-747.82K	12.3M	-1.56M	14.59M
Common Stock	11.19K	14.51K	22.97K	3.84K	11K	33K	4.53K	4.53K	6.8K	42.32K
Retained Earnings	-32.24M	-41.12M	-52.44M	-60.58M	-69.72M	-111.22M	-49.48M	-59.16M	-88.47M	-111.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.68M	4.59M	8.25M	6.61M	21K	21K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.15M	-8.02M	-9.85M	-6.33M	-7.93M	-18.86M	-6.56M	-7.51M	-7.18M	-14.73M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.34%	-0.56%	-0.23%	0.36%	-0.25%	-1.38%	0.65%	-0.14%	0.04%	-1.05%
Net Income	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Depreciation & Amortization	10.29K	16.68K	24.53K	16.35K	10K	32K	380.69K	373.09K	177.38K	116.71K
Stock-Based Compensation	0	0	0	0	0	0	654.53K	218.28K	478.89K	1.96M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	3.83M	524.39K	685.42K	569.65K	701K	22.06M	-527.06K	-294.07K	21M	1.59M
Working Capital Changes	-117.29K	-478.38K	577.51K	1.13M	487K	-2.65M	-55K	1.56M	486.92K	3.29M
Change in Receivables	7.44K	-58.21K	37.08K	13.33K	16.79K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	295.77K	202K	207K	-67K	0	0	0	0
Cash from Investing+	-16.76K	-20.96K	-12.65K	0	0	964K	-3.28K	-36.28K	-1.3M	-6.05M
Capital Expenditures	-16.76K	-20.96K	-12.65K	0	0	-8K	-3.28K	-36.28K	-79.22K	-57.91K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	9.57M	8.47M	9.25M	4.07M	6.6M	26.04M	7.04M	16.25M	2.66M	29.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-8.36K	-8.36K	-8.36K	-8.36K	-8K	-8K	-8K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	-25K	-30K	8K	0	0	-3.8M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.15M	-8.02M	0	-6.33M	-7.93M	-18.87M	-6.57M	-7.54M	-12.03M	-14.79M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.56%	1%	-	-0.25%	-1.38%	0.65%	-0.15%	-0.59%	-0.23%
FCF per Share	-8225.04	-11648.77	-	-4301.44	-1328.42	-1275.64	-235.96	-163.00	-15.98	-0.79
FCF Conversion (FCF/Net Income)	0.58x	0.99x	0.88x	0.79x	0.87x	0.49x	0.94x	0.80x	0.24x	0.68x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-439.15%	-141.32%	-185.43%	-217.44%	-818.28%	-706.34%	-142.71%	-162.12%	-545.67%	-332.67%
Debt / Equity	-	-	-	-	-	-	-	0.01x	-	0.01x
Interest Coverage	-	-	-	-	-	-179.77x	-11.53x	-	-1592.72x	-4.26x
FCF Conversion	0.58x	0.99x	0.88x	0.79x	0.87x	0.49x	0.94x	0.80x	0.24x	0.68x

Frequently Asked Questions

Growth & Financials

TuHURA Biosciences, Inc. (HURA) grew revenue by 0.0% over the past year. Growth has been modest.

TuHURA Biosciences, Inc. (HURA) reported a net loss of $20.4M for fiscal year 2024.

Dividend & Returns

TuHURA Biosciences, Inc. (HURA) has a return on equity (ROE) of -332.7%. Negative ROE indicates the company is unprofitable.

TuHURA Biosciences, Inc. (HURA) had negative free cash flow of $19.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

TuHURA Biosciences, Inc. (HURA) 10-Year Financial Performance & Capital Metrics

HURA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$18M +40.7%
Net Income -$22M +26.0%
EPS (Diluted) -1.21 +89.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -332.67% +39.0%
ROIC -
Debt/Equity 0.01
Interest Coverage -4.26 +99.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM11.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM91.74%

ROCE

10Y Avg-283.61%

5Y Avg-278.35%

3Y Avg-285.19%

Latest-229.18%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	10.29K	16.68K	24.53K	16.35K	10K	32K	0	0	0	116.71K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10.29K	-16.68K	-24.53K	-16.35K	-10K	-32K	0	0	0	-116.71K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.62%	-0.47%	0.33%	0.39%	-2.2%	1%	-	-	-
Operating Expenses+	6.2M	8.3M	11.15M	8.38M	8.13M	21.54M	7.25M	9.93M	29.76M	17.53M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.84M	3.3M	4.02M	4.72M	4.5M	9.72M	2.38M	2.01M	4.14M	4.2M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.36M	5M	7.13M	3.66M	3.63M	11.81M	4.88M	7.93M	9.4M	13.34M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	16.22M	0
Operating Income+	-6.21M	-8.32M	-11.17M	-8.4M	-8.14M	-21.57M	-7.25M	-9.93M	-29.76M	-17.65M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.32%	-0.34%	-0.34%	0.25%	0.03%	-1.65%	0.66%	-0.37%	-2%	0.41%
EBITDA+	-6.2M	-8.3M	-11.15M	-8.38M	-8.13M	-21.54M	-6.87M	-9.56M	-29.59M	-17.53M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.43%	-0.34%	-0.34%	0.25%	0.03%	-1.65%	0.68%	-0.39%	-2.09%	0.41%
D&A (Non-Cash Add-back)	10.29K	16.68K	24.53K	16.35K	10K	32K	380.69K	373.09K	177.38K	116.71K
EBIT	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.18M	-6.39M	-9.93M	-29.3M	-17.54M
Net Interest Income+	108	457	33.24K	60.7K	75K	-120K	-629.29K	57.35K	70.98K	-3.78M
Interest Income	108	457	33.24K	60.7K	75K	0	0	57.35K	89.67K	361.63K
Interest Expense	0	0	0	0	0	120K	629.29K	0	18.69K	4.14M
Other Income/Expense	-2.65M	239.06K	36.35K	350.27K	-982K	-16.73M	238.47K	566.34K	447.89K	-4.03M
Pretax Income+	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.04%	0.09%	-0.38%	0.28%	-0.13%	-3.2%	0.82%	-0.34%	-2.13%	0.26%
Net Income (Continuing)	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14525.00	-12950.00	-9491.48	-5525.00	-1532.00	-2805.85	-903.04	-324.48	-11.29	-1.21
EPS Growth %	-0.89%	0.11%	0.27%	0.42%	0.72%	-0.83%	0.68%	0.64%	0.97%	0.89%
EPS (Basic)	-14525.00	-12950.00	-9491.48	-5525.00	-1532.00	-2805.85	-903.04	-324.48	-11.29	-1.21
Diluted Shares Outstanding	626	688	1.19K	1.47K	5.97K	14.79K	27.83K	46.28K	752.91K	18.66M
Basic Shares Outstanding	626	688	1.19K	1.47K	5.97K	14.79K	27.83K	46.28K	752.91K	18.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.32M	7.87M	7.05M	4.03M	2.76M	11.79M	5.68M	14.74M	4.16M	19.61M
Cash & Short-Term Investments	6.16M	6.59M	5.97M	3.72M	2.39M	10.54M	5.55M	14.25M	3.67M	12.66M
Cash Only	6.16M	6.59M	5.97M	3.72M	2.39M	10.54M	5.55M	14.25M	3.67M	12.66M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	18.39K	76.59K	39.52K	26.19K	0	0	0	101.42K	334.44K	222.7K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	214.7K
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	671.45
Other Current Assets	0	1.21M	1.03M	280.25K	365K	1.26M	135.13K	390.35K	159.33K	316.35K
Total Non-Current Assets+	36.02K	40.29K	28.41K	12.06K	181K	1.75M	721.04K	452.32K	202.99K	356.3K
Property, Plant & Equipment	0	0	0	0	2K	150K	617.14K	418.55K	202.99K	322.53K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	36.02K	40.29K	28.41K	12.06K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	179K	1.6M	103.9K	33.77K	0	33.77K
Total Assets+	6.36M	7.91M	7.07M	4.04M	2.94M	13.54M	6.4M	15.2M	4.36M	19.97M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.47%	0.24%	-0.11%	-0.43%	-0.27%	3.61%	-0.53%	1.37%	-0.71%	3.58%
Total Current Liabilities+	627.45K	1.3M	1.64M	2.07M	2.67M	2.78M	7.15M	2.87M	3.6M	5.33M
Accounts Payable	627.45K	1.27M	1.48M	1.74M	2.01M	2.22M	413.79K	1.92M	1.87M	3.15M
Days Payables Outstanding	22.26K	27.81K	22K	38.95K	73.4K	25.31K	-	-	-	9.86K
Short-Term Debt	0	0	0	0	0	0	644.07K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	33.09K	160.43K	325.21K	664K	561K	456K	675K	137K	1.16M
Current Ratio	10.07x	6.03x	4.30x	1.94x	1.03x	4.24x	0.79x	5.13x	1.16x	3.68x
Quick Ratio	10.07x	6.03x	4.30x	1.94x	1.03x	4.24x	0.79x	5.13x	1.16x	3.64x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	869.58K	28.14K	1.12K	0	0	182K	0	20.74K	2.32M	42.7K
Long-Term Debt	0	0	0	0	0	0	0	0	2.32M	0
Capital Lease Obligations	0	0	0	0	0	0	0	20.74K	0	42.7K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	869.58K	28.14K	1.12K	0	0	182K	0	0	0	0
Total Liabilities	1.5M	1.33M	1.64M	2.07M	2.67M	2.96M	7.15M	2.89M	5.92M	5.37M
Total Debt+	0	0	0	0	0	0	644.07K	138.22K	2.34M	202.54K
Net Debt	-6.16M	-6.59M	-5.97M	-3.72M	-2.39M	-10.54M	-4.9M	-14.11M	-1.32M	-12.45M
Debt / Equity	-	-	-	-	-	-	-	0.01x	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-179.77x	-11.53x	-	-1592.72x	-4.26x
Total Equity+	4.86M	6.58M	5.44M	1.97M	263K	10.58M	-747.82K	12.3M	-1.56M	14.59M
Equity Growth %	6.91%	0.35%	-0.17%	-0.64%	-0.87%	39.23%	-1.07%	17.45%	-1.13%	10.36%
Book Value per Share	7766.25	9556.19	4559.75	1337.55	44.07	715.37	-26.87	265.83	-2.07	0.78
Total Shareholders' Equity	4.86M	6.58M	5.44M	1.97M	263K	10.58M	-747.82K	12.3M	-1.56M	14.59M
Common Stock	11.19K	14.51K	22.97K	3.84K	11K	33K	4.53K	4.53K	6.8K	42.32K
Retained Earnings	-32.24M	-41.12M	-52.44M	-60.58M	-69.72M	-111.22M	-49.48M	-59.16M	-88.47M	-111.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.68M	4.59M	8.25M	6.61M	21K	21K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.15M	-8.02M	-9.85M	-6.33M	-7.93M	-18.86M	-6.56M	-7.51M	-7.18M	-14.73M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.34%	-0.56%	-0.23%	0.36%	-0.25%	-1.38%	0.65%	-0.14%	0.04%	-1.05%
Net Income	-8.86M	-8.08M	-11.14M	-8.05M	-9.13M	-38.3M	-7.02M	-9.37M	-29.32M	-21.68M
Depreciation & Amortization	10.29K	16.68K	24.53K	16.35K	10K	32K	380.69K	373.09K	177.38K	116.71K
Stock-Based Compensation	0	0	0	0	0	0	654.53K	218.28K	478.89K	1.96M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	3.83M	524.39K	685.42K	569.65K	701K	22.06M	-527.06K	-294.07K	21M	1.59M
Working Capital Changes	-117.29K	-478.38K	577.51K	1.13M	487K	-2.65M	-55K	1.56M	486.92K	3.29M
Change in Receivables	7.44K	-58.21K	37.08K	13.33K	16.79K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	295.77K	202K	207K	-67K	0	0	0	0
Cash from Investing+	-16.76K	-20.96K	-12.65K	0	0	964K	-3.28K	-36.28K	-1.3M	-6.05M
Capital Expenditures	-16.76K	-20.96K	-12.65K	0	0	-8K	-3.28K	-36.28K	-79.22K	-57.91K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	9.57M	8.47M	9.25M	4.07M	6.6M	26.04M	7.04M	16.25M	2.66M	29.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-8.36K	-8.36K	-8.36K	-8.36K	-8K	-8K	-8K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	-25K	-30K	8K	0	0	-3.8M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.15M	-8.02M	0	-6.33M	-7.93M	-18.87M	-6.57M	-7.54M	-12.03M	-14.79M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.56%	1%	-	-0.25%	-1.38%	0.65%	-0.15%	-0.59%	-0.23%
FCF per Share	-8225.04	-11648.77	-	-4301.44	-1328.42	-1275.64	-235.96	-163.00	-15.98	-0.79
FCF Conversion (FCF/Net Income)	0.58x	0.99x	0.88x	0.79x	0.87x	0.49x	0.94x	0.80x	0.24x	0.68x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-439.15%	-141.32%	-185.43%	-217.44%	-818.28%	-706.34%	-142.71%	-162.12%	-545.67%	-332.67%
Debt / Equity	-	-	-	-	-	-	-	0.01x	-	0.01x
Interest Coverage	-	-	-	-	-	-179.77x	-11.53x	-	-1592.72x	-4.26x
FCF Conversion	0.58x	0.99x	0.88x	0.79x	0.87x	0.49x	0.94x	0.80x	0.24x	0.68x

Frequently Asked Questions

Growth & Financials

TuHURA Biosciences, Inc. (HURA) grew revenue by 0.0% over the past year. Growth has been modest.

TuHURA Biosciences, Inc. (HURA) reported a net loss of $20.4M for fiscal year 2024.

Dividend & Returns

TuHURA Biosciences, Inc. (HURA) has a return on equity (ROE) of -332.7%. Negative ROE indicates the company is unprofitable.

TuHURA Biosciences, Inc. (HURA) had negative free cash flow of $19.4M in fiscal year 2024, likely due to heavy capital investments.